Febuxostat is an active xanthine oxidase (XO) inhibitor which is widely used in the treatment of hyperuricaemia. We aimed to evaluate the predictive performance of a pharmacokinetic-pharmacodynamic (PK-PD) model of the hypouricaemic effects of febuxostat.
Introduction
Hyperuricaemia has been recognized as an independent risk factor for the incidence of gout attacks and ischaemic cardiovascular diseases, such as myocardial infarction [1] [2] [3] . Lifestyle modification (e.g. diet, exercise) is recommended for all asymptomatic patients having serum urate levels >8.0 mg dl À1 (475.8 μmol l À1 ), whereas pharmacological treatment is recommended for patients having serum urate levels of >9.0 mg dl À1 , in order to attain levels <6.0 mg dl À1 [4] . Among currently available hypouricaemic agents, febuxostat (2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid) appears to be one of the most frequently prescribed agents, particularly for patients with renal impairments. To the best of our knowledge, no attempts have been made to predict individualized maintenance doses of febuxostat on the basis of patients' clinical characteristics, which may be associated with the interindividual variability in febuxostat's pharmacokineticspharmacodynamics (PK-PD) and endogenous urate levels. A pharmacometric approach for analysing, understanding and interpreting drug concentration profiles, drug effects and disease data generated in preclinical and clinical trials, as well as in real-world clinical practice, has attracted much attention [5, 6] . Recently, we have reported a PK-PD model of the hypouricaemic effects of febuxostat using data obtained from preapproval clinical trials and in vitro experiments on xanthine oxidase (XO) inhibition with febuxostat [7] . As our original PK-PD model was formulated using data obtained from preapproval clinical trials, no information on comorbidity or drug interactions were incorporated into it. In the present study, we evaluated our PK-PD model of febuxostat effects using datasets obtained from patients in the real-world clinical practice, and explored any comorbidities and/or drug interactions that might influence the predictive performance of this model.
Methods

Data collection
We searched for patients aged ≥20 years who had received febuxostat at Tokyo Women's Medical University Hospital from March 2011 to December 2015, using the electronic medical records. Exclusion criteria comprised a history of receiving another XO inhibitor prior to febuxostat administration, changes in febuxostat doses during treatment, a lack of the data required for operating the PK-PD model [e.g. serum urate levels and estimated glomerular filtration rate (eGFR)] and a clinical indication for a drug for preventing tumour lysis syndrome following chemotherapy. The study protocol was approved by the institutional review board at Tokyo Women's Medical University Hospital (#3939) prior to the study initiation.
We retrieved patients' demographic data [i.e. gender, age, height, weight and body mass index (BMI)], baseline values for serum biochemistry [aspartate transaminase (AST), alanine aminotransferase (ALT), albumin, creatinine and urate], doses and duration of febuxostat treatment, concomitant medications (i.e. loop diuretics, thiazide diuretics, losartan, benzbromarone, probenecid, or mizoribine), and the presence of comorbidity (e.g. diabetes mellitus). Serum urate and creatinine data in traditional units (mg dl À1 ) and after conversion to SI units (μmol l À1 ) for these two substances were 59.48 and 88.4, respectively. We calculated eGFR using the formula proposed for Japanese patients by the Japanese Society of Nephrology [8] . Chronic kidney disease (CKD) stages for patients were classified according to the guidelines of the American College of Physicians [9] . We collected patients' data for a maximum of 180 days from the commencement of febuxostat administration as far as initial doses were kept constant.
Sensitivity analysis of the original PK-PD model
For the original PK-PD model, we adopted the enzyme kinetic parameter (i.e., Michaelis-Menten constant; K m ) of XO and the inhibition constant (i.e., K i ) of febuxostat to XO that were obtained from in vitro experiments performed with XO specimens purified from bovine milk, as no relevant data were available for human liver XO. A brief description of the original PK-PD model is included in the Appendices. Although there was a good correlation between serum urate levels predicted by the model and those observed following febuxostat administration, we recognized that our original model overestimated the observed values by 27%. In our previous study [7] , we made no attempts to improve the predictive performance of the model by arbitrarily modifying any of the model parameters because no external datasets were available for validating our original PK-PD model. However, in the present study we were able to perform a sensitivity analysis of the original model, to improve its predictive performance because we collected new independent datasets on the hypouricaemic effects of febuxostat for external validation.
We performed a sensitivity analysis using the datasets collected in our previous study [7] . The newly collected datasets were used solely for external validation. In particular, we performed a Monte Carlo simulation for each dataset, using one of the model parameters (K i , K i 0 , K m , F oral , and f u ), which was altered over a range of 10 times below and above the reference value, while keeping the remaining parameters unaltered to observe resultant effects on the predicted serum urate levels. Thereafter, we selected another parameter and repeated the procedure in the same manner. We adopted a mixed-type inhibition model for febuxostat as shown in Appendix. As a result, there are two inhibition constants (K i and K i 0 ) and K m of XO as model parameters for sensitivity analysis. The ranges of input parameters tested were from 0.06 nmol l À1 to 6.0 nmol l À1 for K i , from 0.31 nmol l À1 to 31 nmol l À1 for K i ', and from 0.27 μmol l À1 to 27 μmol l À1 for K m . We performed the sensitivity analysis of the predictive performance of the PK-PD model with regard to changes in the oral bioavailability (F oral ) from 6.5% to 100%, and in the plasma unbound fraction of the drug (f u ) from 0.09% to 9.0%. Mean percentage prediction errors relative to those observed were calculated according to the following equation:
where UA obs is the mean serum urate level observed in the original articles and UA pred is that predicted by the sensitivity analysis. We selected a set of model parameters that would give the PK-PD model the best predictive performance according to the results of the sensitivity analysis.
Evaluation study
Firstly, we assessed the overall predictive performance of the model by comparing all measured serum urate levels and the 95% prediction intervals. In brief, we performed 10 Monte Carlo simulations for trough serum urate levels for each patient, using patient's body weight, baseline serum urate levels, febuxostat dose, febuxostat treatment duration, and baseline eGFR values. We calculated mean values and 95% prediction intervals for the predicted trough serum urate levels every day throughout the treatment period and compared them with actual measured levels. Secondly, we assessed the accuracy of the model-based prediction for serum urate levels for each patient. Correlations between predicted trough serum urate levels and those observed during the administration of febuxostat were analysed using the orthogonal regression method. When multiple measurements for serum uric acid were available from a patient, we used the earliest measured value. We also assessed whether the predictive performance of the model was affected by patients' renal function.
Thirdly, we assessed the time-dependent changes in the predictive performance of the model. In brief, we assessed the predictive performance of the model for data obtained from a treatment duration of <10 days (short duration), 10-30 days (intermediate duration), and >30 days (long duration). When multiple measurements for serum urate were available for a patient, we adopted the earliest measurements within the same treatment duration.
We studied whether the presence of comorbidities, drug interactions and other clinical backgrounds influenced the predictive performance of the PK-PD model. We examined the contribution of the following the variables: demographic characteristics (i.e. gender, age and body weight), biochemical data (i.e. serum levels of AST, ALT, albumin and eGFR), concomitant medications (i.e. loop or thiazide diuretics, losartan, benzbromarone and mizoribine), the implementation of haemodialysis and the presence of comorbidity (e.g. heart failure and diabetes mellitus).
Statistical analysis
We analysed the correlations between predicted and observed trough serum urate levels during the administration of febuxostat using an orthogonal regression method. When multiple measurements for serum urate levels were available from a patient, we adopted the first value measured after the initiation of febuxostat. For multivariate regression analysis, we selected variables with a P value of <0.05 in univariate regression analyses. We analysed collinearity between any of the above variables, and then we selected one of these for multivariate analysis in the light of clinical relevance. We adopted a forward, step-wise, variable selection method for the multivariate regression analysis. In brief, starting with no variable in the model, we added a variable whose inclusion in the regression model gave the most statistically significant improvement in the data fitting according to Akaike's information criterion (AIC), and repeated this process until no variable improved the model to a significant extent. Nevertheless, we imposed a limitation on the number of clinical variables to be included in the final regression model, comprising the PK-PD model with supplemental clinical factors, to avoid the overfitting of the model. In brief, we conducted a fivefold cross-validation test as follows. The total datasets were randomly divided into five subsets (20% of the datasets each). Then, each of the five subsets was used as a validation set, with the remaining subsets as training data to fit the model. As a result, we obtained five fitting models and five validation statistics (R 2 ). The model with the best validation statistics was selected as the final model. Statistical analysis was performed using JMP® 13 (SAS Institute Inc., Cary, NC, USA). Microsoft® Excel® 2016 (ver. 16) was used for preparing the figures. Monte Carlo simulation was performed using STELLA® ver. 9.0.3 software (iSee systems, Inc. Lebanon, NH, USA). P values <0.05 were considered to be statistically significant.
Results
Patients
In total, 1199 eligible data values were retrieved from 168 patients. Patients' demographic and clinical data are summarized in Table 1 . The majority of the patients were old, non-obese males, with a mean [± standard deviation (SD)] age of 60.5 ± 17.7 years and a BMI of 23.6 ± 4.7 kg m À2 .
Serum urate level in the pretreatment period was 9. and 2% were undergoing haemodialysis. The mean dose of febuxostat was 12.5 ± 4.8 mg day À1 (range 5-40 mg day À1 ).
The mean (±SD) observation period was 35 ± 28 days (range 2-177 days). With regard to the use of uricosuric agents, no patients were receiving probenecid but some (3.6%) were receiving benzbromarone.
Sensitivity analysis
The results of the sensitivity analysis for the original PK-PD model are shown in Figure 1 . Relative prediction errors for serum urate levels compared with measured levels appeared to be positively or negatively associated with values for each PK and PD parameter within the ranges. Regarding enzyme kinetics and inhibition parameters, prediction error was negatively correlated with the K i of XO for febuxostat over a range of several times above and below the reference value obtained in the experiments performed using bovine milk XO. This indicated that an error in the assumption of the K i value for human XO based upon comparative nonhuman XO data would substantially influence the predictive performance of the model. The prediction error of the model negatively and positively correlated with the K i ' and K m of XO for febuxostat, respectively; however, the magnitude of the effect elicited by changing K i 0 over a range of several times below and above the reference value and that elicited by using K m of either bovine and human XO appeared less than that elicited by changing K i over a range of several time below and above the reference value. Thus, we arbitrarily decided to adopt a K i value of 1.2 nmol l À1 (i.e. twofold greater than that obtained for bovine milk XO) for the evaluation study, assuming that the K i of human XO for febuxostat would be twofold greater than that for bovine milk XO. Regarding the PK parameters of febuxostat, we adopted arbitrarily fixed values of 65% for F oral and 0.9% for fu. There are multiple reasons why we chose these values in our previous report [7] . Briefly, it was shown that after oral administration of C 14 -labelled febuxostat in six healthy subjects, the mean cumulative recovery of radioactivity in the excreta was 94% (49% in the urine and 45% in the faeces) of the dose over 9 days. These data indicate that the F oral of the drug in humans would be at least 50%, or even greater. In addition, F oral values measured in dogs and rats were 48% and 73%, respectively [7] . As shown in Figure 1 , the relative prediction error would be less sensitive to changes in F oral above 50%. In addition, the f u of febuxostat was shown to be less sensitive to renal function: the f u in patients with normal renal function and those with mild, moderate and severe renal dysfunction was reported to be 0.9%, 0.9%, 0.8% and 1.2%, respectively [10] . As a result, we adopted fixed values of 0.9%, 0.9%, 0.8% and 1.2% for f u according to renal function in the present study. According to the data obtained from the sensitivity analysis (Figure 1 ), we considered that the interindividual variability in F oral and f u might have had a smaller influence on the predictive performance of the model as compared with that of K i .
Evaluation study
In total, 810 of 1199 serum urate levels (67.8%) measured in 168 patients were within the 95% prediction intervals of the model-based predictions (Figure 2 ). By contrast, serum urate levels measured in two patients did not fall within this interval (Figure 2) , and their serum urate levels never dropped below 15.0 mg dl À1 , despite the drug treatment. After scrutinizing the clinical records of the patients, we observed that they had presented with either acute heart or kidney failure after initiating febuxostat treatment (Figure 2 ). The eGFR of all remaining patients showed no significant (P = 0.08) changes during treatment (33.3 ± 2.3 ml min À1 1.73 m À2 )
from the baseline (38.3 ± 2.1 ml min À1 1.73 m À2 ).
We also examined the predictive performance of the model during an early period of febuxostat treatment in 24 patients who underwent serum urate measurements more than four times within 10 days after the commencement of febuxostat treatment. The results indicated that 87% of the predicted values were within the 95% prediction intervals (data not shown).
There was a good linear correlation between the observed serum urate levels (sUA obs ) and those predicted (sUA pred ) (Figure 3 ), as follows: sUA obs = 1.18 × sUA pred + 0.26 (r = 0.68; P < 0.01). The mean (95% onfidence interval) duration of febuxostat treatment over which serum urate was measured was 20 (17-23) days. When regression lines were calculated, stratified by severity of CKD, statistically significant correlations were observed: sUA obs = 1.22 × sUA pred À 1.39 in patients with eGFR >50 ml min We examined the predictive performance of the model using data obtained for short treatment duration (<10 days; n = 80), intermediate treatment duration (10-30 days; n = 86) and long treatment duration (>31 days; n = 50). The results showed significant correlations between the predicted serum urate levels and those observed for data obtained from the short treatment duration and intermediate treatment durations as follows: sUA obs = 1.6 × sUA pred À 1.7 (r = 0.54; P < 0.01; n = 80) and sUA obs = 2.0 × sUA pred À 4.0 (r = 0.38; P < 0.01; n = 86), respectively. However, no significant correlation was observed between predicted serum urate levels and those observed for data obtained from the long treatment duration: sUA obs = 1.37 × sUA pred -1.29 (r = 0.10; P = 0.51; n = 50).
The results of multivariate regression analysis for exploring clinical factors for improving the predictive performance of the PK-PD model are summarized in Table 2 . We found that the inclusion of diabetes mellitus, eGFR, and the concomitant use of loop diuretics as independent variables, as well as sUA pred , further improved the predictive performance of the present PK-PD model (r = 0.78; P < 0.01) as compared with that for sUA pred alone (r = 0.68). We confirmed that there was no significant multicollinearity between four variables (data not shown) and the respective variables had a variance of inflation factor close to 1.0 (Table 2) . A crossvalidation test revealed that serum ALT levels and the concomitant use of mizoribine caused overfitting of the multivariate regression analysis model. There was no interaction between sUA pred and the other variables. Consequently, we selected the following equation as the final prediction model: sUA obs = 3.30 + 0.81 × UA pred -0.03 × eGFR + 0.30 × (1 for loop diuretics users and 0 for non-users) -0.47 × (1 for those presenting with diabetes mellitus and 0 for others) (r = 0.77; P < 0.01; Table 2 ). The final model incorporating clinical variables may improve overall predictive performance compared with the basic PK-PD model may improve overall predictive performance (AIC, 621.3) compared with that of the modified PK-PD model only (AIC, 663.2).
Discussion
Our PK-PD model may be useful for predicting the hypouricaemic effects of febuxostat, unless patients develop acute renal or heart failure ( Figure 2) . The modified PK-PD Figure 2 Observed serum urate levels for all patients during febuxostat treatment and the 95% prediction intervals predicted by the pharmacokinetic-pharmacodynamic model. For better visibility, the data retrieved within a month after the commencement of the drug are shown in the inset. UA, urate Figure 3 Correlation between measured serum urate levels during febuxostat treatment and levels predicted by the modified pharmacokineticpharmacodynamic model. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate model allows for drug doses to be individualized, depending on patients' baseline serum urate level, body weight and renal function. Serum urate levels predicted by the PK-PD model showed good agreement with observed levels, irrespective of patients' renal function (Figure 3 ). To our knowledge, this is the first attempt toward validating the predictive performance of a pharmacometric model for an XO inhibitor, febuxostat, using clinical data obtained from real-world patients. The present PK-PD model may be useful for determining initial febuxostat doses.
Attempts to formulate a PK-PD model for hypouricaemic drugs inhibiting XO have been hampered by the lack of information regarding the K i of these drugs for human XO. Currently, the enzyme kinetic parameters available for XO are obtained from bovine milk XO. Consequently, in a previous study [7] , we formulated the PK-PD model, using PK parameters of febuxostat and endogenous uric acid obtained from hyperuricaemic patients or healthy subjects; however, we adopted the enzyme kinetic parameters of XO for urate synthesis and the K i of febuxostat for XO that were obtained from bovine milk XO. Our original PK-PD model showed good predictive performance for steady-state serum urate levels following febuxostat treatments (r = 0.89) [7] , but there was a systematic overestimation by 27%. In the present study, we performed a sensitivity analysis and observed that the prediction error of the model is most critically dependent on the K i value rather than K i ' or K m values of febuxostat for XO. We considered that our PK-PD model would provide a more accurate prediction, assuming that the K i value of the drug for human XO is twofold greater than that for bovine milk XO. Using the revised K i value, the model was shown to give a better prediction: the regression line for the observed and predicted serum urate levels revealed that the model would give an underestimation of 18% (Figure 3 ). It is difficult to say how much of the absolute error in prediction may be permissible for predicting the hypouricaemic effects of febuxostat. Nevertheless, we assumed that absolute prediction errors within 20% might be acceptable for real-world clinical practice. Consequently, we performed further analyses by assuming the K i value of febuxostat for human XO to be 1.2 nmol l À1 . According to previous reports, there is a species difference in the inhibition kinetics of febuxostat for XO: K i values of febuxostat for XO obtained from bovine milk, rat liver and mouse liver were found to be 1.4 nmol l À1 , 1.8 nmol l À1 and 2.2 nmol l À1 , respectively [11] . Thus, our arbitrary assumption for the K i value of drugs for human liver XO may not be completely justified until the enzyme inhibition kinetics of human liver XO with febuxostat are fully elucidated. At present, we report the results of our external evaluation of the PK-PD model, using datasets retrieved from patients in real-world clinical practice. The predictive performance of the present PK-PD model appeared to be time dependent. Although there were significant correlations between the predicted and observed serum urate concentrations for samples obtained within 30 days after the initiation of febuxostat therapy, no significant correlation was observed for those obtained thereafter. We assume that changes in clinical variables shown to be associated with the PK or PD of the drug (e.g. renal function, concomitant medications and severity of comorbidity) over time might have been responsible for the deterioration in predictive performance. However, we cannot categorically say which variable(s) is the most important. In addition, this finding indicates that the present PK-PD model might be applicable for predicting the hypouricaemic effects of febuxostat within 1 month after the initiation of this drug.
In the present study, we extended our attempts at predicting the hypouricaemic effects of febuxostat by incorporating clinical variables that might influence these effects. Our results revealed that the inclusion of clinical variables to the modified PK-PD model improved the its predictive performance. In particular, the presence of diabetes mellitus appeared to augment the hypouricaemic effects of febuxostat, whereas concomitant use of loop diuretics appeared to attenuate them. At present, the precise mechanisms underlying the contribution of the presence of diabetes mellitus and the concomitant use of loop diuretics are unknown. Nevertheless, a previous study showed that, compared with nondiabetic patients, those with diabetes mellitus had a greater serum urate clearance and clearance ratio of urate to creatinine following the administration of an oral glucose load [12] . The finding that the concomitant use of loop diuretics appeared to attenuate the hypouricaemic effects of febuxostat might be compatible with the findings of previous studies [13] [14] [15] [16] , showing that loop diuretics inhibited urate clearance via its transporter, elevating serum urate levels [17] . Additionally, eGFR negatively correlated with the hypouricaemic effects of febuxostat. As eGFR has already been incorporated into PK models of febuxostat and endogenous urate [7] , the data suggest that eGFR may be associated with the interindividual variability in the PD parameters of the drug. Collectively, further study is needed to improve the prediction performance of the modified PK-PD model by incorporating clinical variables that have been shown to be associated with better predictive performance of the model (Table 2 ) Such a pharmacometric approach is under way for building an ultimate model in our laboratory. Previous studies have reported that dose optimization of another XO inhibitor, allopurinol, might be possible with a pharmacometric approach, by using patients' renal function, fat-free mass and diuretic use [18, 19] . These reports have described the association between the above-mentioned factors and the hypouricaemic effects of allopurinol in terms of the potential PK effects of these factors on oxypurinol, an active metabolite of allopurinol, which is eliminated mainly via the kidneys. Our multivariate regression analyses also demonstrated that renal function and diuretic use were important clinical factors influencing the hypouricaemic effects of febuxostat (Table 2) . Nevertheless, the active metabolites of febuxostat are less likely to influence its pharmacological effect because only trace levels of these active metabolites are present in the plasma [10] .
There were some limitations to the present study. As the analyses were performed using clinical data retrospectively obtained from medical records, no data were available regarding the levels of dietary urate intake, alcohol consumption and adherence to the administered drug. We did not evaluate the urinary excretion of urate, in order to confirm the accuracy of the model for predicting urate production in each patient. Furthermore, we did not measure plasma febuxostat levels for evaluating the accuracy of our PK model. One of the reasons why there still remain unignorable errors in the prediction of the hypouricaemic effects of febuxostat might be attributable to a lack of PK data. We consider that further studies are definitely required to evaluate the performance of the present PK-PD model in estimating the PK of febuxostat and elimination of uric acid. In addition, the prediction performance of the model completely failed in the two patients who developed acute heart failure or renal failure. Thus, further research is warranted to correct these shortcomings.
In conclusion, our modified PK-PD model for the hypouricaemic effects of febuxostat demonstrated an acceptable predictive performance for individualizing febuxostat doses using patients' demographic data, the presence of comorbidities and the use of concomitant medications. Further studies are warranted for validating our model in prospective cohorts with a larger population. 
